Hims & Hers jumps over 13% after HHS Secretary RFK Jr. told Joe Rogan he's pushing to make key peptides more accessible via compounding, potentially boosting the telehealth company's growth in wellness treatments.
BioAtla launches a review to maximize value through sales, partnerships, or deals, while cutting costs with a 70% workforce reduction.
United Therapeutics' ralinepag reduced clinical worsening risk by 55% in PAH phase 3 study. Once-daily oral drug shows strong efficacy; FDA filing planned for 2026.
DBV Technologies reveals new VITESSE Phase 3 data at AAAAI 2026: 83% of kids on VIASKIN Peanut Patch increased safe peanut dose vs 48% on placebo, with excellent safety.
Gyre Therapeutics agrees to acquire Cullgen in $300M all-stock deal, gaining TPD/DAC platform for oncology, pain, and inflammatory diseases. Deal to close Q2 2026 after Cullgen ends Pulmatrix merger.
Rallybio announces a reverse merger with Candid Therapeutics, forming a new Nasdaq-listed company focused on T-cell therapies for autoimmune diseases, backed by over $500M in funding through 2030.
